(Q43588339)

24 November 2017

title

A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection (English)

1 reference

24 November 2017

1 reference

Klimberg IW

1

1 reference

24 November 2017

Cox CE 2nd

2

1 reference

24 November 2017

Fowler CL

3

1 reference

24 November 2017

King W

4

1 reference

24 November 2017

Kim SS

5

1 reference

24 November 2017

Callery-D'Amico S

6

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

24 November 2017

1 reference

24 November 2017

volume

51

1 reference

24 November 2017

issue

4

1 reference

24 November 2017

page(s)

610-615

1 reference

Management of urinary tract infections in adults

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900708-5

7 January 2021

A simplified approach to urinary tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900708-5

7 January 2021

Urinary tract infections in females.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900708-5

7 January 2021

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900708-5

7 January 2021

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900708-5

7 January 2021

Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900708-5

7 January 2021

Colonization and infection with antibiotic-resistant bacteria in a long-term care facility.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900708-5

7 January 2021

Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900708-5

7 January 2021

USA resistance patterns among UTI pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900708-5

7 January 2021

Bullous photodermatosis after lomefloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900708-5

7 January 2021

Photoreactions with a fluoroquinolone antimicrobial: evening versus morning dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900708-5

7 January 2021

10.1016/S0090-4295(97)00708-5

Identifiers

DOI

1 reference

24 November 2017

1 reference